Hereditary Angioedema (HAE) Therapeutics Market Trends

Growth Drivers

• Rising case of HAE: An article published by the Rare Disease Advisor in June 2022, states that HAE episodes lead to 15,000 to 30,000 annual emergency department admissions, in the U.S. As awareness of the condition increases, more individuals are being diagnosed, leading to a greater demand for effective treatments. The rising cases are also attributed to an improved understanding of the genetic factors of the disease. This leads to early detection, and intervention, which boosts the market for therapies aimed at managing symptoms and preventing attacks. The rising patient pool is projected to boost the demand for both acute symptom management and preventive measures to reduce the attack frequency.
• Technological advances in diagnostics and new drug developments: Innovations in biotechnology, including gene editing, monoclonal antibodies, and biologics have led to the creation of more targeted therapies for managing HAE. These advances allow for treatments that not only provide symptom relief but also prevent attacks. Additionally, improved drugs formulations are making therapy more accessible for patients. In January 2024, Pharvaris announced that the U.S. FDA has lifted the clinical hold on the Investigational New Drug (IND) application for deucrictibant for the prophylactic treatment of HAE attacks. As new drugs continue to emerge, alongside technological advancements, the HAE market is poised for significant growth, with better-targeted treatments.

Challenges

• Stringent regulations on new HAE therapies: This poses a significant challenge for the market as the approval process for novel treatments is often lengthy and complex owing to the extensive need for clinical trials to ensure safety and efficacy. Regulatory authorities impose rigorous standards, which can delay the introduction of new therapies, limiting the availability of treatment options for HAE patients.
• High cost of treatment: A major challenge faced by the hereditary angioedema treatment market is the rising cost of advanced treatment for HAE. Owing to the specialized nature of the medications and the small patient population target, many current therapies are severely expensive. This creates financial barriers for patients and healthcare systems, restricting access to effective treatments, mainly in regions with limited healthcare resources.